In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company has predominantly built a portfolio into veterinary products
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Subscribe To Our Newsletter & Stay Updated
